Cargando…
Envisioning clinical trials as complex interventions
Clinical trials are critical components of modern health care and infrastructure. Trials benefit society through scientific advancement and individual patients through trial participation. In fact, billions of dollars are spent annually in support of these benefits. Despite the massive investments,...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378578/ https://www.ncbi.nlm.nih.gov/pubmed/35766902 http://dx.doi.org/10.1002/cncr.34357 |
_version_ | 1784768559494201344 |
---|---|
author | Stensland, Kristian D. Damschroder, Laura J. Sales, Anne E. Schott, Anne F. Skolarus, Ted A. |
author_facet | Stensland, Kristian D. Damschroder, Laura J. Sales, Anne E. Schott, Anne F. Skolarus, Ted A. |
author_sort | Stensland, Kristian D. |
collection | PubMed |
description | Clinical trials are critical components of modern health care and infrastructure. Trials benefit society through scientific advancement and individual patients through trial participation. In fact, billions of dollars are spent annually in support of these benefits. Despite the massive investments, clinical trials often fail to accomplish their primary aims and trial enrollment rates remain low. Prior efforts to improve trial conduct and enrollment have had limited success, perhaps due to oversimplification of the complex, multilevel nature of trials. For these reasons, the authors propose applying implementation science to the clinical trials context. In this commentary, the authors posit clinical trials as complex, multilevel evidence‐based interventions with significant societal and individual benefits yet with persistent gaps in implementation. An application of implementation science concepts to the clinical trials context as means to build common vocabulary and establish a platform for applying implementation science and practice to improve clinical trial conduct is introduced. Applying implementation science to the clinical trials context can augment improvement efforts and build capacity for better and more efficient evidence‐based care for all patients and trial stakeholders throughout the clinical trials enterprise. |
format | Online Article Text |
id | pubmed-9378578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93785782022-10-14 Envisioning clinical trials as complex interventions Stensland, Kristian D. Damschroder, Laura J. Sales, Anne E. Schott, Anne F. Skolarus, Ted A. Cancer Commentary Clinical trials are critical components of modern health care and infrastructure. Trials benefit society through scientific advancement and individual patients through trial participation. In fact, billions of dollars are spent annually in support of these benefits. Despite the massive investments, clinical trials often fail to accomplish their primary aims and trial enrollment rates remain low. Prior efforts to improve trial conduct and enrollment have had limited success, perhaps due to oversimplification of the complex, multilevel nature of trials. For these reasons, the authors propose applying implementation science to the clinical trials context. In this commentary, the authors posit clinical trials as complex, multilevel evidence‐based interventions with significant societal and individual benefits yet with persistent gaps in implementation. An application of implementation science concepts to the clinical trials context as means to build common vocabulary and establish a platform for applying implementation science and practice to improve clinical trial conduct is introduced. Applying implementation science to the clinical trials context can augment improvement efforts and build capacity for better and more efficient evidence‐based care for all patients and trial stakeholders throughout the clinical trials enterprise. John Wiley and Sons Inc. 2022-06-29 2022-09-01 /pmc/articles/PMC9378578/ /pubmed/35766902 http://dx.doi.org/10.1002/cncr.34357 Text en © 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Commentary Stensland, Kristian D. Damschroder, Laura J. Sales, Anne E. Schott, Anne F. Skolarus, Ted A. Envisioning clinical trials as complex interventions |
title | Envisioning clinical trials as complex interventions |
title_full | Envisioning clinical trials as complex interventions |
title_fullStr | Envisioning clinical trials as complex interventions |
title_full_unstemmed | Envisioning clinical trials as complex interventions |
title_short | Envisioning clinical trials as complex interventions |
title_sort | envisioning clinical trials as complex interventions |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9378578/ https://www.ncbi.nlm.nih.gov/pubmed/35766902 http://dx.doi.org/10.1002/cncr.34357 |
work_keys_str_mv | AT stenslandkristiand envisioningclinicaltrialsascomplexinterventions AT damschroderlauraj envisioningclinicaltrialsascomplexinterventions AT salesannee envisioningclinicaltrialsascomplexinterventions AT schottannef envisioningclinicaltrialsascomplexinterventions AT skolarusteda envisioningclinicaltrialsascomplexinterventions |